Chemical-enzyme process synthesis method of isavuconazole
By employing steps such as enzyme-catalyzed asymmetric benzoin reaction, this method solves the problems of difficult-to-obtain raw materials and harsh reaction conditions in existing isaconazole synthesis processes, and provides a simple synthesis method suitable for industrial production.
Patent Information
- Application Number
- CN202410932217.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-08
AI Technical Summary
Existing isoconazole synthesis processes suffer from problems such as the difficulty in obtaining raw materials, complex processes, harsh reaction conditions, and unsuitability for industrial production.
Isaconazole was synthesized in a one-pot process using enzyme-catalyzed asymmetric benzoin reaction, hydroxyl protection reaction, cyclization reaction, deprotection reaction, cyclization reaction of acyl chloride intermediate, reaction with trimethylcyanosilane, and thiolation reaction, using inexpensive and readily available raw materials and mild reaction conditions.
This study establishes a synthetic method for isoconazole that utilizes readily available raw materials, employs a simple process, and operates under mild reaction conditions, making it suitable for industrial-scale production.
Smart Images

Figure BDA0004940058100000011 
Figure BDA0004940058100000021 
Figure BDA0004940058100000051
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of drug synthesis, and particularly relates to a synthesis process method of isavuconazole. Background Art
[0002] Isavuconazole (generic name: Isavuconazonium, trade name: Kangxinbo) English alias: 4-[2-[(2R,3R)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile. The structural formula is shown in formula (1).
[0003]
[0004] Isavuconazole was jointly developed by Japan's Astellas and Switzerland's Basilea Pharmaceuticals, and Pfizer is responsible for the exclusive development and sales rights in China. It was approved by the FDA on March 6, 2015 for the treatment of invasive aspergillosis and invasive mucormycosis in adults. Currently, the drug has been approved in more than 40 countries and regions. In the EU and the United States, isavuconazole has been granted the important status of orphan drug. Isavuconazole is administered intravenously or orally in the form of its water-soluble prodrug isavuconazole sulfate, and is metabolized to the active metabolite isavuconazole in plasma to exert its effect. Summary of the invention
[0005] The object of the present invention is to provide a new chemical enzyme process for synthesizing isavuconazole (1) with readily available raw materials, simple process, mild reaction conditions, green and environmentally friendly properties and suitable for industrialization.
[0006] The technical solution adopted by the present invention is as follows:
[0007] The present invention provides a novel preparation method of isavuconazole, which comprises the following steps:
[0008] 1) Compound (10) and compound (11) are subjected to an asymmetric benzoin reaction catalyzed by benzaldehyde lyase to obtain compound (9);
[0009] 2) Compound (9) is subjected to hydroxyl protection reaction to obtain compound (8);
[0010] 3) Compound (8) undergoes a cyclization reaction with trimethylsulfoxide iodide to obtain compound (7), and compound (7) undergoes a ring-opening reaction with 1,2,4-triazole under the action of NaH to obtain compound (6);
[0011] 4) Compound (6) undergoes a deprotection reaction to obtain compound (5);
[0012] 5) Compound (5) reacts with methanesulfonyl chloride to obtain an acyl chloride intermediate, and the intermediate undergoes a cyclization reaction under the action of a strong base catalyst to obtain compound (4);
[0013] 6) Compound (4) reacts with trimethylsilyl cyanide to obtain compound (3);
[0014] 7) Compound (3) reacts with O,O-diethyl dithiophosphorate to produce compound (2);
[0015] 8) Compound (2) reacts with 4-(2-bromoacetyl)benzonitrile to obtain compound (1);
[0016] The synthesis of compound (8) to compound (5) is a one-pot synthesis.
[0017] The reaction formula of the novel preparation method of isavuconazole of the present invention is shown below:
[0018]
[0019] Furthermore, in step 1), the reaction solvent is a phosphate buffered saline solution with a pH of 7.0±0.2, the reaction temperature is room temperature, the molar ratio of compound (10) to compound (11) is 1:5-1:50, preferably 1:15-1:30, the enzyme used in the reaction is benzaldehyde lyase BAL, whose amino acid sequence is shown in SEQ ID NO.1, and magnesium sulfate and thiamine pyrophosphate THDP are added in the reaction to activate the benzaldehyde lyase; the concentration of compound (10) in the reaction solvent is 10-100 mmol / L, preferably 40-50 mmol / L, the concentration of the enzyme in the reaction solvent is 1-10 mg / L, preferably 2-5 mg / L, the concentration of magnesium sulfate is 0.1-1.0 mM, preferably 0.4-0.5 mM, and the concentration of thiamine pyrophosphate THDP is 0.10-0.50 mM, preferably 0.20-0.25 mM.
[0020] Furthermore, in the reaction of step 2), the protecting group compound that undergoes hydroxyl protection reaction with compound (9) is 3,4-dihydropyran THP, the molar ratio of 3,4-dihydropyran THP to compound (9) is 1.0-3.0:1, preferably 1.5-2.0:1, the catalyst used in the hydroxyl protection reaction is pyridinium p-toluenesulfonate, the molar ratio of pyridinium p-toluenesulfonate to compound (9) is 0.002-0.1:1, preferably 0.04-0.06:1, the reaction temperature is room temperature, and the reaction solvent is dichloromethane.
[0021] Furthermore, in the process of preparing compound (7) by reacting compound (8) with trimethyl sulfoxide iodide in step 3), the reaction solvent is dimethyl sulfoxide or isopropanol, the reaction is carried out in the presence of NaH, the molar ratio of trimethyl sulfoxide iodide to compound (8) is 1.1-1.5:1, the molar ratio of NaH to compound (8) is 1.5-2.5:1, the reaction is carried out at room temperature, and the reaction is terminated when LC-MS monitoring shows that the raw material compound (8) is completely converted.
[0022] Furthermore, in the process of preparing compound (6) by reaction in step 3), the reaction solvent is isopropanol, the molar ratio of 1,2,4-triazole to compound (7) is 1.1-1.5:1, the molar ratio of NaH to compound (7) is 1.5-2.5:1, the reaction is carried out at room temperature, and the completion of the reaction is monitored by TLC.
[0023] Furthermore, the deprotection reaction in step 4) is carried out in isopropanol as solvent, in the presence of methanesulfonic acid, the molar ratio of methanesulfonic acid to compound (6) is 2-5:1, preferably 3-4:1, at room temperature, and the completion of the reaction is monitored by TLC.
[0024] Furthermore, the reaction conditions for preparing the acyl chloride intermediate in step 5) are: using dichloromethane as the reaction solvent, under nitrogen protection, adding triethylamine and methanesulfonyl chloride under 0°C ice bath conditions, the molar ratio of triethylamine to compound (5) is 1.0-4.0:1, preferably 2.0-3.0:1, and the molar ratio of methanesulfonyl chloride to compound (5) is 1.0-3.0:1, preferably 1.5-2.0:1. After the reaction is completed under low temperature stirring under ice bath conditions, water is added for washing, the organic phase is separated and washed with saturated brine, and the solvent is evaporated under reduced pressure to obtain the acyl chloride intermediate.
[0025] Furthermore, in step 5), the acyl chloride intermediate undergoes a cyclization reaction under the action of a strong base catalyst to obtain compound (4) under the following reaction conditions: methanol is used as the reaction solvent, NaOH is added under ice bath conditions at 0°C, the molar ratio of NaOH to the raw material compound (5) in the previous step is 10-15:1, the temperature is raised to room temperature for reaction, and the reaction is completed after monitoring by TLC.
[0026] Furthermore, step 6) uses tetrahydrofuran as a reaction solvent, the reaction is carried out in the presence of ytterbium salt and n-butyl lithium, the molar ratio of trimethylsilyl cyanide to compound (4) is 10-15:1, preferably 12-13:1, the molar ratio of ytterbium salt to compound (4) is 1-3:1, preferably 1.5-2:1, the molar ratio of n-butyl lithium to compound (4) is 4-8:1, preferably 5-6:1, the reaction is carried out at room temperature, and LC-MS is used to detect the reaction until completion.
[0027] Further, in step 7), compound (3) reacts with O,O-diethyl dithiophosphorate to generate thiolation, the molar ratio of the two is 0.1-0.5:1, preferably 0.2-0.3:1, the reaction solvent is a water-isopropanol mixed solvent, the volume ratio of water-isopropanol is 1:5-20, preferably 1:10-15, and the reaction is stirred and refluxed at a temperature of 80-90°C.
[0028] Furthermore, in step 8), compound (2) reacts with 4-(2-bromoacetyl)benzonitrile in a molar ratio of 0.5-2:1, preferably 0.8-1:1, and the solvent is ethanol. The reaction is stirred and refluxed at 80-90°C.
[0029] The beneficial effects achieved by the present invention are as follows: according to the method for preparing isavuconazole provided by the present invention, a key chiral intermediate is constructed by enzyme catalysis using cheap and readily available raw materials, the overall synthetic route has few steps, mild reaction conditions, and a simple synthetic process, and can be used for industrial production. DETAILED DESCRIPTION
[0030] In order to enable those skilled in the art to better understand the technical solution of the present invention, some non-limiting implementation cases are further disclosed below to further illustrate the present invention in detail.
[0031] In the embodiment of the present invention, the amino acid sequence of benzaldehyde lyase BAL is as shown in SEQ ID NO.1, and the source of benzaldehyde lyase BAL is purchased from General Biotechnology (Anhui) Co., Ltd.
[0032] Example 1 Preparation of Compound (9)
[0033]
[0034] In a 3000 mL shaking flask, 50 mmol of compound (10), 1000 mmol of compound (11), 60 mg of magnesium sulfate, 115 mg of thiamine pyrophosphate were added to 1000 mL of phosphate buffered saline (pH 7.0), and benzaldehyde lyase BAL was added at a final concentration of 2.18 mg / ml of pure enzyme. The reaction was carried out at room temperature for 10 h. After the reaction was completed by TLC monitoring, ethyl acetate was added to extract the reaction solution, and the solvent was evaporated to obtain compound (9) with a yield of 78% and a purity of 98% as determined by HPLC.
[0035] 1 H-NMR (CDCl 3 , 400MHz): δ (ppm) 1.40-1.46 (dd, 3H); 3.65-3.8 (s, 1H); 5.01-5.13 (m, 1H); 7.15-7.22 (m, 1H); 7.29-7.36 (m, 1H); 7.60-7.67 (m, 1H).
[0036] ESI-MS [M+H] + =187.
[0037] Preparation of compound (8)
[0038]
[0039] At 30°C, 2.68 mmol of compound (9) and 0.13 mmol of pyridinium p-toluenesulfonate in 2 mL of dichloromethane were added to a 250 mL single-necked round-bottom flask, and 5.35 mmol of 3,4-dihydropyran was slowly added. The mixture was stirred at room temperature for 24 h. After the reaction was completed by TLC monitoring, ethyl acetate was added to extract the reaction solution. The solvent was evaporated to obtain compound (8) with a yield of 87% and a purity of 99% as determined by HPLC.
[0040] 1 H-NMR (CD 3 OD, 400MHz): δ (ppm) 1.33-1.81 (m, 9H); 3.29-3.35 (m, 0.5H); 3.44-3.53 (m, 0.5H); 3.60-6.70 (m, 0.5H);; 3.81-3.89 (m, 0.5H); 4.59-4. 65 (m, 0.5H); 4.67-4.73 (m, 0.5H); 4.79-4.85 (m, 0.5H); 4.50-4.59 (m, 0.5H); 7.20-7.28 (m, 1H); 7.29-7.38 (m, 1H); 7.44-7.50 (m, 1H).
[0041] ESI-MS [M+H] + =271.
[0042] Preparation of compound (5)
[0043]
[0044] Under nitrogen protection, 5 mL of isopropanol, 1.90 mmol of compound (8), 2.28 mmol of trimethylsulfoxide iodide, and 3.79 mmol of NaH were added to a 250 mL double-necked round-bottom flask at room temperature, and stirred at room temperature for 10 h. LC-MS monitoring showed that the raw material compound (8) disappeared and the intermediate (7) was generated. Saturated aqueous ammonium chloride solution was added, extracted with ethyl acetate, and the solvent was evaporated under reduced pressure to obtain an oily liquid, namely compound (7), with a yield of 94%.
[0045] 5 mL of isopropanol, 3.58 mmol of NaH, and 2.14 mmol of 1,2,4-triazole were added to 1.79 mmol of compound (7) and stirred at room temperature for 48 h. After the reaction was completed by TLC monitoring, ethyl acetate was added to extract the reaction solution, and the solvent was evaporated under reduced pressure to obtain an oily compound (6) with a yield of 71%. 0.91 mmol of compound (6) and 3.32 mmol of methanesulfonic acid were added to 5 mL of isopropanol and reacted at room temperature for 12 h. The reaction solution was filtered, the filter cake was washed with isopropanol, the filter cake and 0.46 mmol of potassium carbonate were added to 5 mL of dichloromethane, stirred at room temperature for 1 h, extracted with dichloromethane, and the solvent was evaporated under reduced pressure to obtain a white solid compound (5) with a yield of 36% and a purity of 99.5% as determined by HPLC.
[0046] 1 H-NMR (CD 3 OD, 400MHz): δ (ppm) 0.84 (d, 3H, J = 6.4Hz); 4.25-4.32 (m, 1H); 4.66-4.82 (m, 2H); 6.81-6.98 (m, 3H); 7.69 (s, 1H); 8.21 (s, 1H).
[0047] ESI-MS [M+H] + =270.
[0048] Preparation of compound (4)
[0049]
[0050] Under nitrogen protection, 5 mL of dichloromethane, 0.29 mmol of compound (5), and 0.89 mmol of triethylamine were added to a 100 mL double-necked round-bottom flask at 0°C, and 0.59 mmol of methanesulfonyl chloride was slowly added dropwise, and stirred at low temperature for 2 hours. 50 mL of water was added for washing, and the organic phase was separated and washed with saturated brine, and the solvent was evaporated under reduced pressure, and 5 mL of methanol was added. 3.74 mmol of NaOH was added under ice bath at 0°C, and stirred at room temperature for 1 hour. After the reaction was completed under TLC monitoring, saturated ammonium chloride aqueous solution was added, extracted with ethyl acetate, and the solvent was evaporated under reduced pressure to obtain a light yellow solid compound (4), with a yield of 71% and a purity of 99% as determined by HPLC.
[0051] 1 H-NMR (CD 3 Cl 3, 400MHz): δ (ppm) 1.66 (d, 3H, J = 5.6Hz); 3.21 (q, 1H, J = 5.6Hz); 4.44 (d, 1H, J = 14.7Hz); 4.99 (d, 1H, J = 14.7Hz); 6.74-7.00 (m, 3H); 7.85 (s, 1H); 8.00 (s, 1H).
[0052] ESI-MS [M+H] + =252.
[0053] Preparation of compound (3)
[0054]
[0055] 1 mmol of ytterbium chloride hexahydrate was placed under reduced pressure at 120°C for 6 hours, the compound was suspended in 8 mL of tetrahydropyran under nitrogen protection, and frozen to -78°C, 1.9 mL of n-butyl lithium (1.63 M ethane solvent) was added dropwise to the solution, stirred at room temperature for 5 minutes, cooled to -78°C, 0.8 mL of trimethylsilyl cyanide was added to the mixture, stirred for 10 minutes, and then stirred at room temperature for another 5 minutes, cooled to -78°C, 0.5 mmol of compound (4) was added, the temperature was raised to room temperature, the reaction was carried out for 26 hours, and the reaction was detected by LC-MS to obtain compound (3). The yield was 94%, and the purity was 99% as determined by HPLC.
[0056] 1 H-NMR (CD 3 OD, 400MHz): δ (ppm) 1.11 (d, 3H, J = 7.2Hz); 3.65 (q, 1H, J = 7.1Hz); 4.78 (d, 1H, J =14.3Hz); 4.93 (d, 1H, J = 14.4Hz); 7.00-7.13 (m, 3H); 7.72 (s, 1H); 8.28 (s, 1H).
[0057] ESI-MS [M+H] + =279.
[0058] Preparation of compound (2)
[0059]
[0060] Into a 100 mL single-necked round-bottom flask, 4.30 mmol O,O-diethyl dithiophosphorate, 1.19 mmol compound (3), 2 mL isopropanol and 194 uL water were added in sequence at room temperature, and the temperature was raised to reflux reaction (oil temperature 85°C) with stirring. The reaction was carried out for 15 h, and the mixture was cooled to room temperature, washed with 50 mL of water, extracted with dichloromethane, the organic phases were combined, and the solvent was evaporated under reduced pressure to obtain compound (2) with a yield of 94% and a purity of 99% as determined by HPLC.
[0061] 1 H-NMR (CD3OD, 400MHz): δ (ppm) 1.03 (d, 3H, J = 6.9Hz); 3.66 (q, 1H, J = 6.9Hz); 4. 68 (d, 1H, J = 14.1Hz); 4.92 (d, 1H); 6.91-7.09 (m, 3H); 7.59 (s, 1H); 8.28 (s, 1H).
[0062] ESI-MS [M+H] + =313.
[0063] Preparation of compound (1)
[0064]
[0065] In a 100 mL round-bottom flask, 0.96 mmol of compound (2), 0.96 mmol of 2-bromo-4-cyano-acetophenone and 2 mL of 95% ethanol were added in sequence, and the temperature was raised to 85°C under stirring. The mixture was stirred for 2 h, cooled to room temperature, filtered, and the solid was washed with a methanol: water = 1:1 (v / v) mixed solution to obtain a solid target product (1) with a yield of 70.5% and an HPLC purity of 98%.
[0066] 1 H-NMR (CD3OD, 400MHz): δ (ppm) 1.24 (d, 3H, J = 7.1Hz); 4.26 (q, 1H, J = 7.1Hz); 4.37 (d, 1H, J = 14.4Hz); 5.01 (d, 1 H, J=14.4Hz); 7.01-7.20 (m, 3H); 7.69 (s, 1H); 7.77-7.84 (m, 2H); 8.08 (s, 1H); 8.14-8.19 (m, 2H); 8.21 (s, 1H)
[0067] ESI-MS [M+H] + =438.
[0068] The method of the present invention has been described through preferred implementation cases. Those skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention without departing from the principles and purpose of the present invention.
Claims
1. A chemical-enzymatic synthesis method of isavuconazole, characterized in that: The following steps are involved: 1) Compound (10) and compound (11) are subjected to an asymmetric benzoin reaction catalyzed by benzaldehyde lyase to obtain compound (9); 2) Compound (9) is subjected to hydroxyl protection reaction to obtain compound (8); 3) Compound (8) undergoes a cyclization reaction with trimethylsulfoxide iodide to obtain compound (7), and compound (7) undergoes a ring-opening reaction with 1,2,4-triazole under the action of NaH to obtain compound (6); 4) Compound (6) undergoes a deprotection reaction to obtain compound (5); 5) Compound (5) reacts with methanesulfonyl chloride to obtain an acyl chloride intermediate, and the intermediate undergoes a cyclization reaction under the action of a strong base catalyst to obtain compound (4); 6) Compound (4) reacts with trimethylsilyl cyanide to obtain compound (3); 7) Compound (3) reacts with O,O-diethyl dithiophosphorate to produce compound (2); 8) Compound (2) reacts with 4-(2-bromoacetyl)benzonitrile to obtain compound (1), thereby obtaining the target compound; The reaction formula is as follows:
2. A chemical-enzymatic synthesis method of isavuconazole according to claim 1, characterized in that: In step 1), the reaction solvent is a phosphate buffered saline solution with a pH of 7.0±0.2, the reaction temperature is room temperature, the molar ratio of compound (10) to compound (11) is 1:5-1:50, preferably 1:15-1:30, magnesium sulfate and thiamine pyrophosphate THDP are added in the reaction to activate benzaldehyde lyase, the enzyme used in the reaction is benzaldehyde lyase BAL, and its amino acid sequence is shown in SEQ ID NO.1; the concentration of compound (10) in the reaction solvent is 10-100 mmol / L, preferably 40-50 mmol / L, the concentration of the enzyme in the reaction solvent is 1-10 mg / L, preferably 2-5 mg / L, the concentration of magnesium sulfate is 0.1-1.0 mM, preferably 0.4-0.5 mM, and the concentration of thiamine pyrophosphate THDP is 0.10-0.50 mM, preferably 0.20-0.25 mM.
3. A chemical-enzymatic synthesis method of isavuconazole according to claim 1, characterized in that: In the reaction of step 2), the protecting group compound that undergoes hydroxyl protection reaction with compound (9) is 3,4-dihydropyran THP, the molar ratio of 3,4-dihydropyran THP to compound (9) is 1.0-3.0:1, preferably 1.5-2.0:1, the catalyst used in the hydroxyl protection reaction is pyridinium p-toluenesulfonate, the molar ratio of pyridinium p-toluenesulfonate to compound (9) is 0.002-0.1:1, preferably 0.04-0.06:1, the reaction temperature is room temperature, and the reaction solvent is dichloromethane.
4. A chemical-enzymatic synthesis method of isavuconazole according to claim 1, characterized in that: In the process of preparing compound (7) by reacting compound (8) with trimethyl sulfoxide iodide in step 3), the reaction solvent is dimethyl sulfoxide or isopropanol, the reaction is carried out in the presence of NaH, the molar ratio of trimethyl sulfoxide iodide to compound (8) is 1.1-1.5:1, the molar ratio of NaH to compound (8) is 1.5-2.5:1, the reaction is carried out at room temperature, and the reaction is terminated when LC-MS monitoring shows that the raw material compound (8) is completely converted.
5. The chemical-enzymatic synthesis method of isavuconazole according to claim 1, characterized in that: In the process of preparing compound (6) by reaction in step 3), the reaction solvent is isopropanol, the molar ratio of 1,2,4-triazole to compound (7) is 1.1-1.5:1, the molar ratio of NaH to compound (7) is 1.5-2.5:1, the reaction is carried out at room temperature, and the completion of the reaction is monitored by TLC.
6. The chemical-enzymatic synthesis method of isavuconazole according to claim 1, characterized in that: In step 4), the deprotection reaction is carried out in isopropanol as solvent under the action of methanesulfonic acid, the molar ratio of methanesulfonic acid to compound (6) is 2-5:1, preferably 3-4:1, and the reaction is carried out at room temperature.
7. A chemical-enzymatic synthesis method of isavuconazole according to claim 1, characterized in that: Step 5) The reaction conditions for preparing the acid chloride intermediate are: using dichloromethane as the reaction solvent, adding triethylamine and methanesulfonyl chloride under nitrogen protection and ice bath at 0°C, wherein the molar ratio of triethylamine to compound (5) is 1.0-4.0:1, preferably 2.0-3.0:1, and the molar ratio of methanesulfonyl chloride to compound (5) is 1.0-3.0:1, preferably 1.5-2.0:1, and after the reaction is completed under low temperature stirring under ice bath, water is added for washing, the organic phase is separated and washed with saturated brine, and the solvent is evaporated under reduced pressure to obtain the acid chloride intermediate; Step 5) The acyl chloride intermediate undergoes a cyclization reaction under the action of a strong base catalyst to obtain compound (4) under the following reaction conditions: methanol is used as the reaction solvent, NaOH is added under ice bath conditions at 0°C, the molar ratio of NaOH to the raw material compound (5) in the previous step is 10-15:1, the temperature is raised to room temperature for reaction, and the completion of the reaction is monitored by TLC.
8. The chemical-enzymatic synthesis method of isavuconazole according to claim 1, characterized in that: Step 6) uses tetrahydrofuran as the reaction solvent, and the reaction is carried out in the presence of ytterbium salt and n-butyl lithium. The molar ratio of trimethylsilyl cyanide to compound (4) is 10-15:1, preferably 12-13:1, the molar ratio of ytterbium salt to compound (4) is 1-3:1, preferably 1.5-2:1, and the molar ratio of n-butyl lithium to compound (4) is 4-8:1, preferably 5-6:
1. The reaction is carried out at room temperature and the reaction is detected by LC-MS until completion.
9. The chemical-enzymatic synthesis method of isavuconazole according to claim 1, characterized in that: In step 7), the molar ratio of compound (3) to O,O-diethyl dithiophosphate is 0.1-0.5:1, preferably 0.2-0.3:1, the reaction solvent is a water-isopropanol mixed solvent, the volume ratio of water-isopropanol is 1:5-20, preferably 1:10-15, and the reaction is stirred and refluxed at 80-90°C.
10. The chemical-enzymatic synthesis method of isavuconazole according to claim 1, characterized in that: In step 8), compound (2) reacts with 4-(2-bromoacetyl)benzonitrile in a molar ratio of 0.5-2:1, preferably 0.8-1:1, and the solvent is ethanol. The reaction is stirred and refluxed at 80-90°C.
